KIT and gastrointestinal stromal tumor: The molecular distribution in the metastatic population was as follows: 58.3% of the patients had GIST with a mutation in KIT exon 11, 8.5% in KIT exon 9, 10.6% were KIT/PDGFRA wild type and 4.1% had a PDGFRA exon 18 D842V mutation, whereas 5.3% had another rare mutational status, including KIT exon 13, KIT exon 17, PDGFRA exon 12 and exon 14 mutations.